September 14, 2022 Non RegulatoryUmecrine Cognition secures funding ahead of Phase 2 study of golexanolone in patients with primary biliary cholangitisSTOCKHOLM – September 14, 2022. Umecrine Cognition today announces that the company has secured funding of SEK 41 million for the start of a Phase...
August 10, 2022 Non RegulatoryUmecrine Cognition announces the recruitment of Anders Karlsson as new CEOSOLNA – August 10, 2022. Umecrine Cognition AB today announces that its Board of Directors has appointed Anders Karlsson as new CEO. He succeeds...
July 7, 2022 Non RegulatoryNotice to attend Extraordinary General Meeting in Umecrine Cognition ABThe shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the extraordinary general meeting at 10:00 a.m. on...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.